762 Subject Index
endocannabinoids 5, 14, 17, 149,
410, 480–483, 487, 532
see2-arachidonoyl glycerol (2-
AG)
see2-arachidonylglyceryl ether
(noladin ether)
seeanandamide
seevirodhamine
biosynthesis/production of
149–156, 368, 374, 375
degradation/inactivation/meta-
bolism of 156–164, 369,
376, 483, 486, 487, 490, 495
hypofunction 483
ligands 489
metabolic inhibitors of 155,
161, 162
pharmacology of 164–168
regulation of 169
release of 156
spill-over 376
transporter 484,489,490,495,
499, 369, 376
uptake of 156, 369, 376
endocannabinoid transmembrane
movement 198
accumulation 198
characteristics of 198
endothelium 606,607,609–611,614,
617
endothelium-derivedhyperpolarizing
factor (EDHF) 606, 607,
609
endotoxemia 616
enteric nervous system
ileum 319
entourage effect 6
epilepsy 737
ERK1 61
ERK2 61
Ethanol 133
eukaryotic 289, 294
evolution 284
excitatory neurotransmission 333,
336
central nervous system 332
excretion 662, 680
experimentalautoimmuneencephalo-
myelitis (EAE) 411
extrapyramidalmotorcontrolsystem
354(^18) F 429
FAAH seefatty acid amide hydro-
lase
fast spiking neuron 354
fatty acid amide hydrolase (FAAH)
6, 18, 19, 37, 188, 189, 289,
293, 369, 565, 574, 576, 585,
587, 589, 590, 703
amidase signature sequence
189
catalytic triad 189
characteristics of 189
FAAH gene 566
inhibitors 191, 192
regulation 190
substrate specificity 190
FDG 430
fear conditioning 456
feeding behaviour 134, 559
fertility 565
finger-tapping 437
fish 285, 286, 289, 290
fMRI 426
follicle-stimulating hormone 563
fornix 556
Friend leukemia virus (FLV) 400
Fugu rubripes 285–287, 289, 290
future directions for human
research 744
anti-cancer effects 747
chronic nociceptive pain
746
drug withdrawal treatments
748
inflammatory conditions 745
Crohn’s disease 745
rheumatoid arthritis 745
intractablebreathlessness 748
migraine 748